Theravance Biopharma, Inc. (TBPH) is a publicly traded Healthcare sector company. As of May 21, 2026, TBPH trades at $16.55 with a market cap of $838.25M and a P/E ratio of 7.31. TBPH moved +1.72% today. Year to date, TBPH is -10.15%; over the trailing twelve months it is +75.13%. Its 52-week range spans $7.88 to $21.03. Analyst consensus is buy with an average price target of $16.61. Rallies surfaces TBPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
TBPH financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TBPH recently traded at $16.55. Market cap is $838.25M. P/E ratio is 7.31. Revenue is $109.78M.
| Metric | Value |
|---|---|
| Price | $16.55 |
| Market Cap | $838.25M |
| P/E Ratio | 7.31 |
| EPS | $2.26 |
| Dividend Yield | 0.00% |
| 52-Week High | $21.03 |
| 52-Week Low | $7.88 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $109.78M |
| Net Income | $114.54M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $107.46M | $105.89M | $2.10 |
| 2024 | $64.38M | $-56.42M | $-1.15 |
| 2023 | $57.42M | $-55.19M | $-1.00 |
| 2022 | $51.35M | $872.13M | $11.85 |
6 analysts cover TBPH: 0 strong buy, 3 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.61.